Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $1.880
America/New_York / 3 mai 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 98.95 mill |
EPS: | -0.960 |
P/E: | -1.958 |
Earnings Date: | Aug 02, 2023 |
SharesOutstanding: | 52.64 mill |
Avg Daily Volume: | 3.47 mill |
RATING 2023-05-05 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Neutral | |
P/E: | Buy | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.958 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.33x |
Company: PE -1.958 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.798 - 1.962 ( +/- 4.36%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-03 | Concentra Biosciences, Llc | Buy | 10 000 | Common Stock |
2023-05-03 | Tang Kevin C | Buy | 10 000 | Common Stock |
2023-05-03 | Tang Kevin C | Sell | 5 300 087 | Common Stock |
2023-05-03 | Concentra Biosciences, Llc | Buy | 0 | Common Stock |
2023-05-03 | Salter-cid Luisa | Sell | 20 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-96.23 |
Last 98 transactions |
Buy: 1 025 987 | Sell: 8 913 091 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.880 (0.00% ) |
Volume | 11.60 mill |
Avg. Vol. | 3.47 mill |
% of Avg. Vol | 334.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.